Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM
NCT ID: NCT04267601
Last Updated: 2021-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2448 participants
OBSERVATIONAL
2017-07-06
2021-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus
NCT04810507
Observational Study to Evaluate the Efficacy and Safety of Teneligliptin
NCT03793023
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
NCT05103306
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus
NCT06141980
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
NCT07076056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary endpoint
\- HbA1c change after 24 weeks treatment
Secondary endpoint
* Average rate of change in HbA1c after baseline
* Ratio of subjects with HbA1c\<7% after 24 weeks
* Ratio of subjects with HbA1c\<6.5% after 24 weeks
* Subgroup analysis by gender, age, BMI, medical history, renal function, liver function, conventional DPP4 inhibitors therapy, concomitant Oral Antidiabetic Drug, duration of disease
Safety endpoint : Adverse Event
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anagliptin
Anagliptin treatment for 24weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Understands and is willing to sign an informed consent form (ICF)
* HbA1c≥7.0%
* within 7days before registration, continuing other DPP4is alone or combined therapy for than 8 weeks
Exclusion Criteria
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Korea, Bucheon ST. Mary's hopsital
Bucheon-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JWP-GDL-402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.